WEDNESDAY, DECEMBER 5, 2018

1. MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX).
   Brufsky AM, Crozier JA, Grady I, et al.
   POSTER: OT1-13-01
   ONGOING TRIALS 1 (Hall 1, 5.00 PM – 7.00 PM): Genomic Signatures

2. Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer.
   POSTER: P1-15-07
   ONGOING TRIALS 1 (Hall 1, 5.00 PM – 7.00 PM): Treatment: Neoadjuvant Chemotherapy

THURSDAY, DECEMBER 6, 2018

3. BluePrint molecular subtyping versus HER2 assessment by immunohistochemistry and FISH in the real-world diagnostic setting.
   POSTER: P3-10-22
   POSTER SESSION 3 (Hall 1, 5.00 PM – 7.00 PM): Prognostic and Predictive Factors:
   Predictive Biomarkers for Targeted Therapies

4. Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ~1000 patients across 10 arms of the I-SPY 2 TRIAL.
   POSTER: P3-10-02
   POSTER SESSION 3 (Hall 1, 5.00 PM – 7.00 PM): Prognostic and Predictive Factors:
   Predictive Biomarkers for Targeted Therapies

5. Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ~1000 patients across 10 therapies.
   POSTER: P3-10-06
   POSTER SESSION 3 (Hall 1, 5.00 PM – 7.00 PM): Prognostic and Predictive Factors:
   Predictive Biomarkers for Targeted Therapies

6. LIV-1 expression in primary breast cancers in the I-SPY 2 TRIAL.
   POSTER: P3-10-13
   POSTER SESSION 3 (Hall 1, 5.00 PM – 7.00 PM): Prognostic and Predictive Factors:
   Predictive Biomarkers for Targeted Therapies

FRIDAY, DECEMBER 7, 2018

7. Metabolic syndrome increases risk of recurrence and impacts immune pathways in invasive lobular carcinoma.
   Robinson P, Treece T, Osipo C, et al.
   POSTER DISCUSSION: PD7-04
   SPOTLIGHT SESSION 7 (Stars at Night Ballroom 1 & 2, 7.00 AM – 9.00 AM): Lobular Breast Cancer

8. Molecular subtypes of invasive lobular breast cancer in the I-SPY 2 TRIAL.
   POSTER DISCUSSION: PD7-06
   SPOTLIGHT SESSION 7 (Stars at Night Ballroom 1 & 2, 7.00 AM – 9.00 AM): Lobular Breast Cancer
10. Comparison of breast cancer molecular subtyping by Immunohistochemistry and by BluePrint® next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris.

   Darrigues L, Slembrouck L, Mittempergher L, et al.

   POSTER: P4-02-07

11. MammaPrint identifies 46% of patients, age ≤50 years with oncotype RS 18-30, as low risk and safe to forgo chemotherapy.


   POSTER: P4-08-10

   POSTER SESSION 4 (Hall 1, 7.30 AM – 9.00 AM): Prognostic and Predictive Factors: Prognostic Factors — Clinical Testing and Validation

12. Comparative analyses of the prognostic value of oncotype and mammmaprint using the National Cancer Database.

   Ibraheem AF, Olopade O, Huo D.

   POSTER: P4-08-12

   POSTER SESSION 4 (Hall 1, 7.30 AM – 9.00 AM): Prognostic and Predictive Factors: Prognostic Factors — Clinical Testing and Validation

13. Decentralized beta testing of MammaPrint and BluePrint NGS kit at University Hospitals Leuven and Curie Institute.


   POSTER: P4-08-25

   POSTER SESSION 4 (Hall 1, 7.30 AM – 9.00 AM): Prognostic and Predictive Factors: Prognostic Factors — Clinical Testing and Validation

14. Economic Impact of MammaPrint (70-gene signature) in a clinical high risk population: A 10yr Markov model, 6,000-patient retrospective analysis of US claim data.

   Blumencranz LE, Høst-Ragab A, Retèl VP et al.

   POSTER: P5-15-08

   POSTER SESSION 5 (Hall 1, 7.30 AM – 9.00 AM): Psychosocial, QOL, and Educational Aspects: Cost Effectiveness

VISIT BOOTH #607 to learn more about the MammaPrint and BluePrint tests for early-stage breast cancer